To compare the outcomes and treatment-related toxicities of two chemoradiotherapy schedules given to the patients with unresectable locally advanced non-small cell lung cancer (NSCLC): sequential chemotherapy with accelerated hypofractionated radiotherapy (SCRT), and concurrent chemotherapy with standard radiotherapy (CCRT), 68 patients from two prospective clinical trials were included. Thirty-four patients were treated with SCRT using an accelerated hypofractionated radiation schedule, 34 patients received CCRT with standard radiation. Between the two treatment groups there were no significant differences in terms of overall survival, progression-free survival (PFS), locoregional-PFS or distant metastasis-PFS. For the SCRT group, the median survival time and 2-and 4-year overall survival rates were 19 months, 38.2%, and 23.5%, respectively, and for the CCRT group these were 19 months, 44.1%, and 19.6%. Esophageal and constitutional toxicities were more pronounced in the CCRT group, while there was no significant difference in pulmonary toxicities. The results suggest that for unresectable stage III NSCLC, the outcomes of SCRT with accelerated hypofractionated radiotherapy and CCRT with standard radiotherapy are similar, but the toxicities associated with treatment are less in the SCRT group.
Introduction
Non-small cell lung cancer (NSCLC) is a common cause of cancer death worldwide (1) . Surgical resection is the preferred treatment for localized NSCLC with earlier stages, but more than one-third of patients present with locally advanced, unresectable tumors. Radiotherapy (RT) is an important treatment modality for patients in the advanced stages of NSCLC. The current standard of care for locally advanced NSCLC is concurrent chemoradiotherapy (CCRT) with a platinum-based regimen (2) (3) . However, CCRT is associated with an elevated incidence of toxicities and there is no consensus on the optimal chemotherapy (CHT) regimens and their scheduling, so that it has not been widely accepted (4) . There still remains significant interest in the attempt to improve treatment effect by use of non-conventional dose-fractionations of RT.
An individual data-based meta-analysis reported by Aupérin et al. (5) directly compared CCRT with sequential CHT-RT (that is, CHT followed by RT; SCRT). In that study, CCRT was shown to result in better overall survival (OS) compared with SCRT, predominantly due to an improvement in locoregional control, because there was no difference between the two treatment options in distant failure rates. The advantage of CCRT due to locoregional control might be related to the well-known radio sensitizing effect of CHT. It is therefore reasonable to wonder if more aggressive RT, which is also more effective in locoregional control, could substitute for concurrent use of CHT and reduce toxicity. In the present study we analyzed the outcomes of patients from two prospective clinical trials of combined CHT and RT in locally advanced NSCLC. One group of patients received SCRT using accelerated hypofractionated RT (HypoRT; the SCRT group), and the other received CCRT using conventional dose-fractionated RT (the CCRT group).
Materials and Methods

Patients
Between April 2006 and April 2008, a single-arm phase II trial (6) was conducted at our hospital with 34 patients to evaluate the feasibility and efficacy of sequentially using CHT and accelerated HypoRT in locally advanced NSCLC (the SCRT group). Beginning in January 2007, we participated in a multiple center, randomized phase III clinical trial (7) to evaluate the effects of consolidation CHT after CCRT, also in patients with locally advanced NSCLC. Because the number of our enrollment was too small (7 patients), in the present analysis we included patients in the same trial at Sun Yat-Sen University Cancer Hospital (29 patients), a total of 36 patients enrolled from January 2007 to April 2008 (the CCRT group). Two patients in the CCRT group were subsequently excluded from the analysis, with one refusing treatment and another not completing treatment due to pulmonary tuberculosis. Thus, each group (SCRT and CCRT) had 34 patients.
Eligibility criteria for the two trials were identical, consisting of histologically-or cytologically-proven NSCLC with unresectable stage III (AJCC 2003), excluding malignant pleural or pericardial effusion; measurable diseases on a computed tomography (CT) image; older than 18 years; KPS  70; and adequate bone marrow, liver, renal and pulmonary functions. All patients provided written informed consent before treatment. Staging workup for the SCRT group included CT of the thorax and abdomen, CT or magnetic resonance imaging (MRI) of the brain, and bone scan. For the CCRT group, CT/MRI of the brain and a total body fludeoxyglucose (FDG)-positron emission tomography (PET) scan were mandatory, except for patients with T4N0 seen on chest CT, for whom the PET was optional.
Treatment Schedule
SCRT group: Two cycles of CHT were given before RT. RT was started within 3 weeks of the completion of induction CHT (after the patient had recovered from the toxicity of CHT). After RT was completed, two cycles of CHT could be administered at the patients' own request and at the discretion of the treating radiation oncologist. A maximum of 4 cycles of CHT were permitted for each patient. The CHT regimen consisted of vinorelbine plus cisplatin, administered as intravenous (IV) vinorelbine 25 mg/m 2 on days 1 and 8, and IV cisplatin 25 mg/m 2 on days 1, 2, and 3; cycles were repeated at 21-day intervals. An accelerated HypoRT regimen was administered, in which RT was given in two phases with no split between phases. In the first phase, a total dose of 50 Gy was given in 20 fractions (fx): 2.5 Gy/fx, once per day, and 5 fx/week. For the second phase, the fraction dose was changed from 2.5 Gy to 3 Gy, without any amendment of target volumes. A total dose of 65 Gy in 25 fx, or 68 Gy in 26 fx, was delivered to 19 and 15 patients, respectively. The mean biological effective dose (BED) of this group was 83.7 Gy (α/β 5 10 Gy).
CCRT group: CHT and RT were started on the same day. The CHT regimen during the concurrent period consisted of docetaxel (20 mg/m 2 , IV) and cisplatin (20 mg/m 2 , IV) weekly for 6 weeks. Administration of consolidation CHT was based on a randomized selection result and was conducted within 4-8 weeks of completion of CHT-RT. The consolidation regimen was docetaxel (35 mg/m 2 , IV) and cisplatin (35 mg/m 2 , IV), both on days 1 and 8. This regimen was repeated every 3 weeks. CHT was continued for up to 3 cycles, as long as there was no unacceptable toxicity or evidence of disease progression. All patients received conventional fractionated RT, 5 days/week, once daily fractions, 2 Gy/fx to a total dose of 60-66 Gy according to normal tissue constraints. Finally, 19, 3, 1, 10, and 1 patients received 66, 64, 62, 60, and 56 Gy, respectively. The mean BED was 76.4 Gy (α/β 5 10 Gy).
Radiotherapy Procedure
All patients were treated with three-dimensional conformal radiation therapy (3D-CRT). Intensity-modulated RT was not allowed in either of the trials. Gross tumor volume (GTV) was defined as the primary tumor and all lymph nodes .1 cm in the short-axis dimension, or positive on the FDG-PET scan. In the SCRT group, the GTV was derived from the post-CHT scan for primary tumor, whereas the GTV for lymph nodes was delineated according to the pre-CHT scan. The clinical target volume (CTV) was the GTV expanded by an isotropic margin of 0.5-0.8 cm. The planning target volume (PTV) was created by expanding the CTV by an anisotropic margin of 0.8-1.5 cm according to the primary tumor movement, as evaluated by fluoroscopy. No elective nodal irradiation was permitted. The spinal cord, esophagus, heart, and normal lung (defined as both lungs minus PTV) were outlined as critical organs. Treatment planning was performed with Pinnacle 3D treatment planning system software (Philips Radiation Oncology Systems, Milpitas, CA). Tissue inhomogeneity corrections were applied to all dose calculations. The planning goal was to deliver the prescription dose to at least 95% of the PTV while meeting normal tissue constraints according to the respective protocol.
Evaluation and Follow-up
During treatment patients were monitored weekly for toxicity. The first follow-up was conducted 4-6 weeks after completion of RT or CHT-RT treatment. After the whole treatment was completed, the follow-up was performed every 3 months for the first 2 years, and every 6 months thereafter. Physical examination, assessment of performance status, and chest CT were conducted at each visit, and any significant toxicity was recorded. Any further investigations were arranged as clinically indicated. Treatment failures which were defined as disease progression according to the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.0, were classified as locoregional recurrence and distant metastasis. Locoregional recurrence included the primary tumor and regional lymph nodes; distant metastasis included any site beyond the primary tumor and regional lymph nodes. Treatment related toxicities were judged on the basis of patients' complaints, physical examination and relevant exams, and graded chiefly at the discretion of the treating physicians, according to the Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. However, when facing complicated cases, a panel discussion would be held to reach the final scores of the toxicities.
Statistical Analysis
The chi-squared test was used to assess dichotomized variables, and the t-test to compare the means between the treatment groups on the same continuous variables. The primary endpoint analyzed was overall survival (OS). Secondary endpoints included progression free survival (PFS), locoregional-PFS (LR-PFS), and distant metastasis-PFS (DM-PFS), where locoregional and distant failures were defined as locoregional or distant, respectively, recurrence as a component of the site of first failure.
The survival function was computed from the initiation of treatment using Kaplan-Meier estimates, and the log-rank test was used to assess the equality of the survival functions across the treatment groups. Univariate and multivariate Cox analysis was performed to test for the independent influence of potential prognostic factors on OS (gender, age, Karnofsky performance status (KPS), histological subtype, staging by PET, clinical stage, GTV volume, BED, consolidation CHT, and treatment group). To assess the risk of developing grade 3 radiation esophagitis as a function of clinical and dosimetric variables, a binary logistic regression model was constructed. Probability (p)-values  0.05 were considered statistically significant, and statistical tests were based on a two-sided significance level. Statistical analyses were performed using Statistical Package for the Social Sciences (SPSS) software (SPSS, Chicago, IL, Version 16.0). Table I shows the distribution of pre-treatment patient characteristics in the two groups. The mean age was significantly 
Results
Patient Demographic and Clinicopathologic Characteristics
Compliance and Toxicity
All patients completed the planned induction or concurrent chemotherapy. All but one patient completed the planned radiation doses. This patient was in the CCRT group and planned to treat with 60 Gy. The hiccups and fatigue induced by treatment made him stop radiation at 56 Gy. No patient interrupted radiation because of treatment-related toxicities, except for one patient in the CCRT group who delayed RT one week due to radiation esophagitis. Consolidation CHT was received by 31 patients in the SCRT group; 19 and 12 received two cycles and one cycle, respectively. In the CCRT group, 11, 2, and 3 patients underwent 3, 2, and 1 cycles of consolidation CHT.
Hematological toxicities were moderate and tolerable during the RT period of both groups. No one experienced grade 4-5 RT or CCRT-associated non-hematological toxicities in either group. Grade 2-3 complications were shown in Table II . Esophageal and constitutional toxicities were more pronounced in the CCRT group than the SCRT, while there was higher in the SCRT group than the CCRT group. A greater percentage of the patients in the CCRT group had PET due to the difference of staging workup requirements between the two trials. There were more patients diagnosed with stage IIIB in the CCRT group (Table I) .
Outcomes
Median follow-up of patients in total and survivors only was 20 months (range: 4-63 months) and 55 months (range: 44-63 months), respectively, in the SCRT group, and 20.5 months (range: 3-53 months) and 45 months (range: 39-53 months) in the CCRT group. Eight patients in each group were alive at the time of this analysis. Of these, all 8 patients were without evidence of disease in the SCRT group, two patients were with the disease in the CCRT group.
There were no significant differences in terms of OS, PFS, LR-PFS, and DM-PFS between the two groups ( Figure 1 no significant difference in pulmonary toxicities. Only one patient died from treatment toxicity in the two groups. This patient received CCRT followed by consolidation CHT, and died after two cycles of consolidation CHT due to chemotherapy induced electrolyte disturbances and myelosuppression.
The dosimetric parameters most commonly used for lung and esophagus were compared between the two groups.
There was no significant difference in lung V20 (the percent of total lung volume receiving 20 Gy) between the two groups (p 5 0.964). The esophagus V55 was significantly higher (p , 0.001) in the CCRT group ( In this analysis, only the treatment group was statistically significant (p 5 0.03).
Discussion
In the present comparative study, according to the results indicated by all endpoints used in this analysis, the two treatment groups (sequential CHT accelerated HypoRT and concurrent CHT standard RT) had similar outcomes but patients who received CHT and RT sequentially experienced significantly less toxicities.
Historically patients with locally advanced NSCLC were treated with RT alone, but the results were disappointing with median survival of only about 10 months. Many randomized trials have since established the importance of integrating CHT with RT. Initially, studies showed that the addition of induction CHT to RT could reduce distant metastases and increase median survival to 14 months, with a 2-year OS of 14-27% (8) (9) . According to subsequent trials (10-12), CHT administered concurrently with RT could further improve upon the results obtained from sequential treatment, increasing the median survival to 17 months and the 2-year OS to 34-39%, with greater local control. However, to our knowledge, none of the comparisons between concurrent and sequential CHT-RT varied in RT schedules. The outcomes of our concurrent CHT-RT cohort were comparable to the historical controls (5) , while the sequential group compared favorable with the relevant history studies and similar to concurrent use, which might be, at least partly, caused by different RT intensities.
For locally advanced NSCLC, control of locoregional disease is very important; uncontrolled local lesions within the lung and mediastinum are often the direct cause of death, and locally persistent or recurrent thoracic disease might also serve as seeds for distant metastases. Therefore, better local control can translate into longer survival (13) (14) . One approach to improve local control is to take advantage of the radiosensitizing effect of concurrent CHT and RT. In the meta-analysis of Aupérin et al. (5) higher local control was achieved when CCRT was applied, and also contributed to a better OS. Optimizing the dose and fractionation of the radiation is another way to enhance the effectiveness of RT.
In the present study, no difference was found in local control between the two groups. We think the aggressiveness of the RT schedule of the sequential modality compensated for the non-concurrent effect of CHT and was responsible for the similar survival of both groups.
Accelerated HypoRT can potentially improve local control in NSCLC, owing to the greater effect of the larger fraction and shorter overall treatment time. However, hypofractionated schedules have often been avoided in curative treatment because more side effects are expected to accompany the larger dose per fraction. With the development of radiation techniques, however, renewed enthusiasm is being given to hypofractionation. In the present study, the toxicity profile of our CCRT (with standard RT) cohort paralleled other studies with similar the raputic protocols (15) (16) (17) (18) . Although concurrent CHT studies have found that weekly docetaxel and cisplatin was associated with relatively low toxicity and good compliance (4), in our study toxicities were significantly worse when compared with the SCRT group. In addition, the average age of patients in the SCRT group was higher than the CCRT, which might make these patients more susceptible to treatment-related toxicity. Therefore, we believe that in terms of developing toxicities, concurrent CHT is more aggressive than HypoRT. Some may argue that the higher incidence of radiation esophagitis in the CCRT group could be due to a greater radiation dose delivered to the esophagus, because the dosimetric parameters were much higher in this group. However, analysis of both clinical and dosimetric factors using a logistic regression model for the clinical more interested grade 3 esophagitis showed that only the combined modality had predictive value. We presume that differences in biological effect caused by differences in fractionation might blur the power of dosimetric parameters.
Theoretically, it is possible to achieve better local control by using CCRT with more intense RT. Some phase I and phase II studies (19) (20) (21) showed good results and acceptable toxicities when using CCRT with dose-escalated conventional fractionated RT. However, in the recent trial of the Radiation Therapy Oncology Group (RTOG 0617) (22) , when applied concurrently with CHT a higher radiation dose of 74 Gy did not benefit OS when compared with the lower standard dose of 60 Gy. One of the possible explanations for this counter intuitive finding was the higher toxicities in the higher dose group (23) . The same results were obtained for HypoRT in the only randomized trial that has compared sequential and concurrent chemoradiation using an accelerated HypoRT scheme (there was no difference in outcomes) (24), although encouraging results had been found in smaller studies (25, 26) . Perhaps such combinations can be used in the future when less toxic agents have been developed and with more advanced radiation techniques such as proton radiation.
It is important to recognize the limitations of our study. Firstly, more patients in the CCRT group received PET scan for staging, which might result in stage migration, or the "Will Rogers phenomenon" (27) , because FDG-PET functional imaging can detect metastatic disease in lung cancer earlier than was possible before (28) . Indeed, this might have led to a selection bias due to the non-randomized design of our study. However, upon univariate and multivariate analysis it was not found to impact OS. Further ruling out the likelihood of the effect from stage migration on OS was the fact that the rate of distant metastases was identical in both groups. Secondly, the CHT agents were different between the two groups, and it is difficult to determine how much this diversity could have influenced effectiveness. A meta-analysis (29) of patients with advanced NSCLC showed that docetaxel was superior to vinorelbine whenever it was used as monotherapy or combined with other agents for the first-line therapy. Because of this we believe that the similar outcomes of the two treatment groups can be attributed specifically to the RT used in the SCRT group (HypoRT). Thirdly, the sample size was relatively small which might lower the statistically power, and therefore we could not draw a confirmed conclusion that the outcomes of these two treatment schedules were equivalent. However, the actual aim of this retrospective study was not to reach a definite decision but to find some indications for the further study design, and we did not find an overt trend toward either treatment in terms of outcome.
To the best of our knowledge, there has been no prior comparative study, randomized or non-randomized, that compared sequential with concurrent chemoradiation with different RT schedules in locally advanced NSCLC.
Despite the several acknowledged shortcomings mentioned above, some strengths should also be recognized. All the patients were treated in the same period, which made our study more reliable than historical comparisons. Moreover, the two groups were from two respective prospective studies, so that the treatment within each group was relatively homogeneous and the follow-up and assessments were quite strict.
In summary, this study showed that for locally advanced NSCLC, SCRT with a more aggressive RT (here, accelerated HypoRT), obtained similar outcomes as CCRT with standard RT, while reducing treatment toxicities. A randomized trial to verify these results is warranted.
